Seven days of low-dose orally administered murine type I interferon does not cause priming in vivo.
In vivo, low-dose orally administered type I interferon (LDOA IFN) therapy has been shown to provide beneficial effects in a number of diseases. These diseases vary in nature (viral, autoimmune, and neoplastic), yet LDOA IFN therapy is able to provide effective treatment. Despite the growing knowledge of the efficacy of such treatment and ongoing human clinical trials, the mechanism by which LDOA IFN acts remains largely unknown. In this study, we examined the phenomenon known as "priming" as a potential mechanism by which LDOA IFN effects may be mediated. Priming is a phenomenon in which pretreatment of cells or entire organisms with type I IFN causes significantly enhanced IFN production after induction of the endogenous IFN system by virus or polyI:C. This phenomenon of priming has been exploited in commercial industry for the mass production of type I IFN for medical and research use. It was found that LDOA IFN treatment did not cause priming in vivo.
Bosio
E
E
Department of Microbiology, University of Western Australia, Nedlands, Perth, Australia 6009.
Beilharz
M W
MW
D000284:Administration, Oral; D000818:Animals; D000998:Antiviral Agents / Q000008:administration & dosage / Q000097:blood; D004306:Dose-Response Relationship, Immunologic; D004334:Drug Administration Schedule; D007370:Interferon Type I / Q000008:administration & dosage* / Q000096:biosynthesis* / Q000097:blood; D051379:Mice; D008807:Mice, Inbred BALB C
D000998:Antiviral Agents; D007370:Interferon Type I